180 related articles for article (PubMed ID: 10937059)
1. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers.
Proca DM; Niemann TH; Porcell AI; DeYoung BR
Appl Immunohistochem Mol Morphol; 2000 Jun; 8(2):120-5. PubMed ID: 10937059
[TBL] [Abstract][Full Text] [Related]
2. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls.
Geramizadeh B; Boub R; Rahsaz M
Indian J Pathol Microbiol; 2007 Jul; 50(3):507-10. PubMed ID: 17883119
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers.
Porcell AI; De Young BR; Proca DM; Frankel WL
Mod Pathol; 2000 Jul; 13(7):773-8. PubMed ID: 10912937
[TBL] [Abstract][Full Text] [Related]
4. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver.
Morrison C; Marsh W; Frankel WL
Mod Pathol; 2002 Dec; 15(12):1279-87. PubMed ID: 12481008
[TBL] [Abstract][Full Text] [Related]
5. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material.
Al-Muhannadi N; Ansari N; Brahmi U; Satir AA
Ann Hepatol; 2011; 10(4):508-15. PubMed ID: 21911893
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review.
Lamps LW; Folpe AL
Adv Anat Pathol; 2003 Jan; 10(1):39-43. PubMed ID: 12502967
[TBL] [Abstract][Full Text] [Related]
7. MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma.
Niemann TH; Hughes JH; De Young BR
Cancer; 1999 Oct; 87(5):295-8. PubMed ID: 10536355
[TBL] [Abstract][Full Text] [Related]
8. The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver.
Labib OH; Harb OA; Khalil OH; Baiomy TA; Gertallah LM; Ahmed RZ
J Gastrointest Cancer; 2020 Mar; 51(1):88-101. PubMed ID: 30784016
[TBL] [Abstract][Full Text] [Related]
9. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.
Kakar S; Muir T; Murphy LM; Lloyd RV; Burgart LJ
Am J Clin Pathol; 2003 Mar; 119(3):361-6. PubMed ID: 12645337
[TBL] [Abstract][Full Text] [Related]
10. The Das-1 immunostain is useful for discriminating metastatic colon adenocarcinoma from cholangiocarcinoma and hepatocellular carcinoma.
Zimmerman RL; Das KM; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(6):1369-72. PubMed ID: 12375050
[TBL] [Abstract][Full Text] [Related]
11. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
[TBL] [Abstract][Full Text] [Related]
12. Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors.
Amarapurkar AD; Rege JD; Joshi AS; Vaiphei K; Amarapurkar DN
Indian J Pathol Microbiol; 2006 Jul; 49(3):341-4. PubMed ID: 17001880
[TBL] [Abstract][Full Text] [Related]
13. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.
Lau SK; Prakash S; Geller SA; Alsabeh R
Hum Pathol; 2002 Dec; 33(12):1175-81. PubMed ID: 12514785
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid hormone-related peptide expression in primary and metastatic liver tumours.
Roskams T; Willems M; Campos RV; Drucker DJ; Yap SH; Desmet VJ
Histopathology; 1993 Dec; 23(6):519-25. PubMed ID: 8314235
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples.
Siddiqui MT; Saboorian MH; Gokaslan ST; Ashfaq R
Cancer; 2002 Feb; 96(1):49-52. PubMed ID: 11836703
[TBL] [Abstract][Full Text] [Related]
17. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
Chu PG; Ishizawa S; Wu E; Weiss LM
Am J Surg Pathol; 2002 Aug; 26(8):978-88. PubMed ID: 12170084
[TBL] [Abstract][Full Text] [Related]
19. Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases.
Terracciano LM; Glatz K; Mhawech P; Vasei M; Lehmann FS; Vecchione R; Tornillo L
Am J Surg Pathol; 2003 Oct; 27(10):1302-12. PubMed ID: 14508391
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver.
Lei JY; Bourne PA; diSant'Agnese PA; Huang J
Am J Clin Pathol; 2006 Apr; 125(4):519-25. PubMed ID: 16627262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
